Page 391 - Read Online
P. 391

Paap et al. Plast Aesthet Res 2020;7:36                                      Plastic and
               DOI: 10.20517/2347-9264.2020.121                                  Aesthetic Research




               Review                                                                        Open Access


               The interaction between hyaluronidase and

               hyaluronic acid gel fillers - a review of the literature
               and comparative analysis


               Michael K. Paap , Rona Z. Silkiss 2
                             1
               1 University of California, San Diego School of Medicine, La Jolla, CA 92093, USA.
               2 Division of Oculofacial Plastic Surgery, California Pacific Medical Center, San Francisco, CA 94102, USA.

               Correspondence to: Dr. Rona Z. Silkiss, Division of Oculofacial Plastic Surgery, California Pacific Medical Center, 711 Van Ness
               Ave, Ste 340, San Francisco, CA 94102, USA. E-mail: drsilkiss@silkisseyesurgery.com
               How to cite this article: Paap MK, Silkiss RZ. The interaction between hyaluronidase and hyaluronic acid gel fillers - a review of the
               literature and comparative analysis. Plast Aesthet Res 2020;7:36. http://dx.doi.org/10.20517/2347-9264.2020.121
               Received: 22 May 2020    First Decision: 19 Jun 2020    Revised: 21 Jun 2020    Accepted: 28 Jun 2020    Published: 12 Jul 2020

               Academic Editor: Wen-Guo Cui    Copy Editor: Cai-Hong Wang    Production Editor: Tian Zhang

               Abstract
               Hyaluronic acid (HA) is the most common component of aesthetic fillers. Many formulations exist, each exhibiting
               properties that are manifestations of individual molecular modifications. The enzyme hyaluronidase degrades
               hyaluronic acid and can therefore be injected into soft tissue to reduce suboptimally placed HA fillers or to
               reverse local ischemic complications. The clinically available varieties of hyaluronidase may be derived from crude
               animal extracts or genetically engineered from recombinant human DNA. Different HA fillers are not uniformly
               dissolved by a single source hyaluronidase, and hyaluronidase from different sources may have varying efficacy
               in the degradation of HA. Previous studies of subsets of HA fillers and hyaluronidases have provided limited and
               often conflicting data regarding these differences, and a more comprehensive scientific study is needed. In this
               review, the authors describe commonly available formulations of HA and hyaluronidase and review all studies of
               HA-hyaluronidase interaction available via a PubMed and Google Scholar search from 2005 to present, exploring
               trends in the data. Factors determined to confer increased resistance to degradation included higher concentration
               of HA, higher crosslinking density, and status as monophasic versus biphasic. Fillers of the Juvéderm family
               were generally found to be more resistant to degradation than members of the Restylane family. Results are less
               consistent for Belotero Balance. No variety of hyaluronidase was consistently superior at dissolving any variety of
               HA filler. More research is needed to clarify these clinically relevant relationships.


               Keywords: Hyaluronic acid, hyaluronic acid gel, hyaluronidase, dermal fillers, enzymatic degradation, filler
               complications



                           © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0
                           International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
                sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
                as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
                and indicate if changes were made.


                                                                                                                                                    www.parjournal.net
   386   387   388   389   390   391   392   393   394   395   396